Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Mitochondria play a crucial role in the induction and execution of apoptosis. Accordingly, recent suggestions have been made to use agents that directly act on mitochondria to trigger apoptosis so that drug-sensitive and-resistant tumour cells can be eliminated. To test this hypothesis, human hepatocarcinoma HepG2 and its derivative R-HepG2 with doxorubicin (Dox) resistance as a result of expression of P-glycoprotein were used to investigate the effect of lonidamine (LND), a new mitochondrial targeting drug, on the induction of apoptosis. Results from our study indicate that R-HepG2 cells were more sensitive to LND than parental cells in terms of cytotoxicity determined by alamar blue assay. Cell death induced by LND was associated with the hallmarks of apoptosis such as mitochondrial membrane depolarization, release of cytochrome c, phosphatidyl-serine externalization and DNA fragmentation. Moreover, combined treatment of cells with Dox and LND elicited more cell death. Taken together, our results suggest a potential use of LND as an anti-cancer drug to bypass drug resistance and to trigger tumour destruction through apoptosis in HepG2 and R-HepG2 cells. (C) 2002 Elsevier Science Inc. All rights reserved.
著者Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK
期刊名稱Life Sciences
出版年份2002
月份10
日期25
卷號71
期次23
出版社PERGAMON-ELSEVIER SCIENCE LTD
頁次2729 - 2740
國際標準期刊號0024-3205
電子國際標準期刊號1879-0631
語言英式英語
關鍵詞apoptosis; drug resistance; lonidamine; mitochondrial; P-glycoprotein
Web of Science 學科類別Medicine, Research & Experimental; MEDICINE, RESEARCH & EXPERIMENTAL; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY; Research & Experimental Medicine

上次更新時間 2020-06-08 於 01:29